Background: Surgical management of primary melanoma is curative for most patients with clinically localized disease at diagnosis; however, a substantial number of patients recur and progress to advanced disease. Understanding molecular alterations that influence differential tumor progression of histopathologically similar lesions may lead to improved prognosis and therapies to slow or prevent metastasis.
poor outcome for patients diagnosed with a localized primary melanoma. Staging of primary melanomas incorporates histopathological features (thickness, mitotic index, ulceration, and lymph node status) and is generally prognostic of clinical outcome (4) (5) (6) (7) (8) . However, frequently melanoma cell dissemination occurs from primary tumors that are histologically equivalent to nonmetastasizing lesions at diagnosis. Approximately 7% and 30% of patients with localized melanoma at diagnosis (stage I and II, respectively) will suffer a recurrence (9) , and most will then progress to metastatic disease and eventual death (10) . These outcomes suggest that histopathologically similar melanomas may have divergent underlying molecular features influencing their potential to metastasize. Consistent with this concept, messenger RNA (mRNA) or microRNA (miRNA) expression in a variety of cancers is associated with or predicts disease recurrence, progression to metastasis, and other outcome measures (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Collectively, these studies suggest that measurable populations of metastasis-initiating cells are present in a subset of primary tumors. Identifying molecular alterations at cancer diagnosis that are functionally involved in metastatic progression will further elucidate mechanisms used during initiation of the metastatic cascade, which could yield novel therapeutic strategies to disrupt tumor cell dissemination and/or new prognostic biomarkers.
miRNAs are short RNAs that control complex cellular processes through post-transcriptional regulation of target mRNA (21) . Recent studies have shown that altered expression of specific miRNAs is associated with patient outcomes in melanoma and that perturbation of individual miRNAs functionally impacts melanoma cell metastasis (22) (23) (24) (25) (26) . These and other studies have analyzed global miRNA expression comparing nevi to primary melanoma, primary to metastatic melanoma, or metastatic melanomas with differing outcomes. However, miRNA expression profiling of primary melanoma tissues of different outcomes has not been examined. Moreover, the mechanisms underlying metastatic propensity of a subset of primary melanomas are unclear.
Here, we identified miRNAs associated with aggressive, cutaneous primary melanomas (associated with tumor thickness or recurrence status) by expression profiling of a cohort of clinically well-annotated primary melanoma tissues (n = 92). To discover metastasis-relevant miRNAs, we screened candidates differentially expressed in aggressive vs nonaggressive primary melanomas in a high-throughput in vitro invasion assay and subsequently an in vivo metastasis model. Mechanistically, we examined the effects of invasion-and metastasis-regulating miRNAs on matrix remodeling, a key process during initiation of tumor cell dissemination. Finally, we identified a network of target genes that are potential direct downstream mediators of these phenotypes through regulation of the actin cytoskeleton.
Methods

Clinical Specimens
Primary human melanoma samples were collected at the time of surgery. Informed consent was obtained from all patients and approval acquired by the Institutional Review Board of New York University (NYU) School of Medicine (protocol #10362). All tumors were classified according to the 2009 American Joint Committee on Cancer staging system. Further details are available in Supplementary Methods (available online).
RNA Extraction
From formalin-fixed, paraffin-embedded (FFPE) samples, primary melanoma tissues were macroscopically dissected using disposable scalpels and guided by hematoxylin and eosin (H&E) staining of consecutive sections. RNA extraction was performed with miRNeasy FFPE kit following manufacturer's recommendations. Further details are available in the Supplementary Methods (available online).
MicroRNA Array Analyses
MiRNA expression profiling of FFPE-extracted RNA from primary melanomas was performed by Exiqon, Inc. using dual-color miRCURY™ LNA arrays. The quantified signals were background corrected and normalized using the global Lowess regression algorithm. Data are deposited in GEO (accession: GSE62372). Further details and information on miRNA constructs and cloning, array profiling, real-time quantitative polymerase chain reaction (qPCR), quantification, and mimic transfection are available in the Supplementary Methods (available online).
miRNA Analyses
Further information on miRNA extraction, constructs and cloning, array profiling and analyses, real-time qPCR, quantification, and mimic transfection are available in the Supplementary Methods (available online).
Cell Culture
501MEL cells (gift of Dr. Ruth Halaban, Yale Medical School) were cultured in Optimem + 5% fetal bovine serum (FBS). 451Lu and WM1361a cells (obtained from Coriell) were cultured in Tu2%, which contains 80% MCDB153 (Sigma Aldrich) and 20% L15 (Cellgro), and supplemented with approximately 2% heat-inactivated FBS, 1.68 mM CaCl, and 5 μg/mL bovine or human insulin. SK-MEL-147 and SK-MEL-173 (gift of Dr. Houghton, MSKCC), and SK-MEL-28 (ATCC)) cells were cultured in DMEM + 10% FBS. All cells were grown in a humidified incubator at 37°C and 5% CO 2 . All cell lines were derived from human melanoma tumor tissue. Cell lines were initially analyzed by morphologic assessment and gene expression profiling for lineage-specific gene expression (TYR, TRYP1, DCT, TRYP1B, MITF, EDNRB, KIT). Cells were maintained in culture for no more than 25 passages.
Invasion Assay Screen
Briefly, reverse-transfected (Lipofectamine 2000) GFP-expressing metastatic melanoma cells were seeded in 96-well Fluoroblok inserts precoated with fibronectin (10 μg/mL). Cells were incubated for eight to 40 hours at 37°C, 5% CO 2 . Invading cells were imaged and counted using a high-content fluorescent imaging system (Cellomics Arrayscan). Further details on fluorescent cell generation, reverse transfection, invasion assay seeding, and quantification are in the Supplementary Methods (available online).
In Vivo Metastasis Experiments miRNA Overexpression and Cortactin Depletion
Animal experiments were conducted in accordance with guidelines set forth by the Institutional Animal Care and Use Committee (IACUC) of NYU (protocol # 120405-02).
451Lu cells transduced with lentiviral supernatants containing miRNA (pMIRH, System Biosciences) or short hairpin RNA (shRNA) (GIPZ, Open Biosystems) expression constructs were resuspended in growth media at a concentration of 2x10 6 cells/150 μl, aliquoted into microfuge tubes (150 μL), and maintained on ice until injection. Immediately prior to injection, cell aliquots were mixed with 150 μL Matrigel (Becton Dickinson/ Corning). Cell/Matrigel (1:1) suspensions were injected subcutaneously in the right flank of NOD/Shi-scid/IL-2Rγ null (NOG, Taconic) mice (n = 9 per group). Further details are available in the Supplementary Methods (available online).
3' UTR Luciferase Reporter Assay
HEK293T cells were seeded in 96-well plates at 30 000 cell/well and incubated at 37°C and 5% CO 2 for 16 to 24 hours. HEK293T cells were cotransfected with 100 to 200 ng 3'UTR reporter plasmid and 50 nM (3'UTR) of the indicated mimic or control miRNA (Dharmacon) using Lipofectamine 2000 (Invitrogen), following manufacturer's recommendations. 
Statistical Analysis
Other Methods
Descriptions of viral production and transduction, gelatin degradation assays and immunofluorescence, and western blotting are in the Supplementary Methods (available online).
Results
Analysis of the Effects of microRNAs Differentially Expressed Between Aggressive vs Nonaggressive Primary Melanomas on In Vitro Invasion
To identify candidate miRNAs that functionally contribute to early stages of melanoma progression, we profiled the expression of 838 annotated miRNAs by microarray (Exiqon, Inc.) of a well-annotated cohort of 92 cutaneous, primary melanomas of predominantly superficial spreading and nodular histological subtypes, with a minimum of three years of follow-up from initial diagnosis for surviving patients (Supplementary Table 1 , available online). We validated the array platform by reverse transcription quantitative polymerase chain reaction (RT-qPCR) of randomly selected miRNAs (Supplementary Figure 1 , available online). As surrogate clinical parameters of highly "aggressive" tumors, we identified miRNAs differentially expressed between patients whose tumors had or had not recurred (n = 48 and n = 44, respectively) and miRNAs whose expression associates with tumor thickness (Supplementary Table 2 , available online). We hypothesized that some of these miRNAs might impact cell invasion and metastasis.
To test this theory, we developed an automated, 96-well in vitro invasion assay using fluorescently labeled cells and a high-content imaging system as a screening platform. We selected the top 40 candidates based on a combination of fold change and statistical significance between aggressive and nonaggressive tumors, and median probe intensity (expression level, cutoff ≥ 50). We transiently overexpressed candidate miRNAs individually using oligo mimics in two metastatic melanoma cell lines (SK-MEL-147 and 501MEL) and assessed their impact on in vitro invasion using our screening platform (Supplementary Figure 2, available online) . From this initial analysis, we selected 13 miRNAs that suppressed or enhanced invasion in both cell lines in primary screening. We further assessed the effect of their overexpression on in vitro invasion in additional metastatic melanoma cell lines (SK-MEL-28 and SK-MEL-173) (Supplementary Figure 3 
MiR-382 and miR-516b Expression in Aggressive vs Nonaggressive Primary Melanomas
To verify the association of expression of invasion-suppressive miRNA with aggressive primary tumors seen in our initial analyses, we performed further data mining of our existing data set and profiled miRNA expression of an additional set of primary melanoma patient samples (n = 119) (Supplementary Table 3 , available online). We found that miR-382 expression was correlated with thickness in both cohorts (Pearson, r = -0.527, P < .001, r = -0.300, P < .001) and associated with recurrence-free survival (RFS) in both datasets (median cut-off, Wilcoxon test, P = .002, P = .06), while miR-516b was correlated with thickness (Pearson, r = -0.364, P < .001, r = -0.161, P = .040), in both data sets but associated with RFS in only one (Wilcoxon test, P = .59, P = .02) ( Figure 2 , A and B). In contrast, the correlation of miR-7 expression with thickness (Pearson, r = -0.253, P = .015) and association with recurrence status (Student's t test, P = .0037) seen in our initial data set did not validate in additional patients (r = 0.086, P = .178 and P = .247, respectively) ( Figure 2C ). Moreover, expression of miR-7 did not associate with RFS in either cohort (Wilcoxon test, P = .43 and P = .69, respectively) ( Figure 2C ). Similar to miR-7, additional miRNA (eg, miR-215 and miR-374b*) that were of interest based on the initial patient data analysis and invasion screening did not validate in this additional cohort of patient samples. In sum, our results demonstrate that miR-382 and miR-516b are less abundant in more vs less aggressive primary melanomas. Collectively, the altered expression of miR-382 and miR-516b in primary melanoma samples in conjunction with their ability to suppress melanoma cell invasion suggests that their dysregulation may have important functional contributions at early stages of melanomagenesis. Based on these findings, we opted to perform additional functional experimentation with miR-382 and miR-516b only.
Effect of miR-382 and miR-516b on Lung Metastasis In Vivo
To assess the impact of miR-382 and miR-516b modulation on melanoma metastasis, we used a xenograft model in which 451Lu melanoma cells (27) implanted subcutaneously in the flanks of NOD/Shi-scid/IL-2Rγ null (NOG) mice metastasize to mouse lungs. Figure 4C , available online). In conjunction with reduced tumor size compared with tumors of the miR-CTRL group, miR-516b's effects on metastasis might be partially proliferation dependent. In contrast, miR-382 suppressed metastasis relative to control in a proliferationindependent manner. In sum, these results identify miR-382 and miR-516b as key suppressors of melanoma metastasis in vivo.
Effect of miR-382 and miR-516b on Extracellular Matrix Remodeling
Early in the metastatic cascade, tumor cells encounter basement membrane and extracellular matrix barriers that must be circumvented to enter circulation and metastasize (1). We reasoned that suppressors of metastasis that are less abundant in aggressive primary melanomas might impair extracellular matrix degradation/remodeling. To assess the effect of metastasis-suppressive microRNA on this process in melanoma, we used fluorescent-gelatin degradation assays as a surrogate in vitro assay. We found that miR-382 expression statistically significantly reduced the degradative capacity of melanoma cells, while miR-516b had no effect in this context (control [scr]: mean = 34.34%, 95% CI = 25.2 to 43.5; miR-382: mean = 20.0%, 95% CI = 13.7 to 26.3, P = .005; miR516b: mean = 30.9%, 95% CI = 18.3 to 43.4, P = .393) (Figure 4 , A-C). This finding suggests that lower expression of miR-382 in primary tumors may enable aggressive behavior of melanoma cells by increasing their capacity to migrate through surrounding stroma. In contrast, miR-516b had no impact on matrix degradation in this model, suggesting it uses different mechanisms or impacts remodeling of different matrix components to effect metastasis suppression.
Identification of Direct miR-382 Targets
To better understand the downstream mechanisms by which miR-382 functions to suppress invasion, metastasis, and matrix remodeling, we identified targets that could potentially mediate these phenotypes. to .05, **P = .001 to .01, and ***P < .001. B) Representative images of invading 501MEL melanoma cells overexpressing SCR control or the indicated miRNA oligo mimics.
Images taken with Cellomics Arrayscan Vti using the 5X objective. miRNA = microRNA. Figure 7D , available online). Analysis of the total number of metastatic foci in mouse lungs revealed a nonsignificant trend toward fewer macrometastases in the shCTTN group (size cutoff = 0, P = .138) ( Figure 6F ). In contrast, we analyzed the number of metastatic foci using increasing size cutoffs and found statistically significantly fewer metastatic foci in the shCTTN group at nearly all cutoffs (Mann Whitney-Wilcoxon tests, P < .05) (Figure 6 , F and G), suggesting CTTN depletion yields fewer large metastatic foci. Collectively, these data are consistent with CTTN as an important mediator of the effects of miR-382; however, modulation of additional targets in combination with CTTN appears necessary to fully recapitulate its effects. 
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Effect of miR-382 Inhibition on In Vitro and In Vivo Properties of Poorly Tumorigenic Melanoma Cells
To more closely model the effect of miR-382 downregulation in aggressive primary melanomas, we inhibited miR-382 using a lentiviral decoy construct (37) in a poorly tumorigenic, primary tumor-derived melanoma cell line (WM1361a) (38) . 
Discussion
Metastatic dissemination of melanoma cells is the key event dictating poor outcomes of patients with localized primary tumors who are typically cured through surgical management (5) . Identification of pathways commonly disrupted at early stages of tumorigenesis that influence melanoma progression might yield key insights into the biology of metastasis and reveal novel strategies for therapeutic intervention. We hypothesized that molecular alterations that influence metastatic potential may be acquired early in a tumor's evolution, and evidence in support of this model has been accumulating for some cancers, including melanoma (42) (43) (44) . We focused on understanding the functional contribution of miRNAs to metastasis initiation in early-stage primary melanoma. Collectively, our data demonstrate that altered expression of specific miRNAs in early-stage primary tumors is a key determinant of metastatic behavior.
In this study, we profiled the miRNA expression of more than 200 FFPE primary melanomas in two sample sets with extensive patient follow-up to identify miRNAs that could impact metastasis initiation. We analyzed the functional effect of miRNA candidates differentially expressed in aggressive vs nonaggressive tumors using in vitro and in vivo metastasis models and elucidated cellular and molecular mechanisms of one of the identified metastasis-regulating miRNAs (miR-382). Collectively, our data identify miR-382 and miR-516b as suppressors of melanoma invasion and metastasis. Interestingly, combined overexpression of miR-382 and miR-516b had no impact beyond that of either miRNA alone on the in vitro invasion capacity of melanoma cell lines (Supplementary Figure 9 , available online), suggesting that they may act through parallel pathways. While our study profiled the expression of more than 200 primary melanoma patient samples, additional samples or samples from other institutions would aid confirmation of the generalizability of our findings. A related limitation of our study is that the effect size of the associations of expression with clinical variables was reduced for both miRNAs in the validation patient set, while other miRNAs did not validate. This finding may be because of the issue of multiple comparison testing, as well as the inherent challenge of measuring molecular changes that may occur only in subpopulations of cells within a tumor.
We focused our efforts on exploring the molecular mechanism(s) employed by miR-382 because of its suppressive effect on invasion and metastasis, and extracellular matrix remodeling, a key feature of cells with metastatic capacity (1, 45) . Expression profiling of melanoma cell lines overexpressing miR-382 indicated a role regulating the actin cytoskeleton. We identified CTTN, RAC1 (RAC), and ARPC2, which are key cytoskeletal regulators, as direct targets and plausible downstream mediators of miR-382. CTTN integrates upstream signaling to promote and stabilize ARP2/3-mediated actin nucleation (36) . ARPC2 is a core structural component of the ARP2/3 complex, which nucleates branched actin networks (46) . RAC is a Rho-family GTPase that regulates a diverse set of cellular processes, particularly cell motility through regulation of actin polymerization (47, 48) . Collectively, these proteins regulate lamellipodia and invadopodia dynamics, which mediate directional migration and matrix remodeling, respectively. Invadopodia are key cellular structures employed by invasive cancer cells to remodel extracellular matrices, which is particularly relevant during local invasion (36, (49) (50) (51) . CTTN is an essential molecule for and quintessential marker of invadopodia (52) . As the key integrator of signaling from several upstream pathways, CTTN is a nodal point of cytoskeletal dynamics (53) . Moreover, CTTN has been found to be upregulated through cancer progression for a variety of tumor types, including melanoma, and is pro-oncogenic in some cancers (reviewed in [54] ). CTTN depletion alone appears to alter the kinetics but not the absolute ability of melanoma cells to metastasize; thus, it may represent a therapeutic target useful to slow disease spread in the adjuvant setting. Collectively, our data suggests that reduction of miR-382 in primary tumors may facilitate matrix remodeling by promoting increased levels of CTTN and other actin regulators, which may induce invadopodia formation or activity and/or promote other cytoskeletal changes.
The phenotype and targets of miR-382 identified here suggest another role as a regulator of lamellipodia. RAC1 is a particularly interesting target in this regard, as it is the core GTPase regulating lamellipodia. RAC1 is essential for proper migration of melanoblasts during development (55) . Melanoma exome sequencing efforts identified a recurrent mutation, P29S, which activates RAC GTPase activity, in 5% to 10% of metastatic melanomas (56, 57) . Moreover, RAC deletion or inhibition in an NRAS-driven melanoma transplant model reduced tumor growth and suppressed metastatic spread (58) . Alteration of upstream regulation of RAC by PREX1/2 in melanoma may also destabilize RAC control, as evidenced by functional studies and PREX2 mutations (59, 60) . Interestingly, mutant-NRAS induced RAC-dependent, invadopodia-mediated matrix degradation in melanocytic cells, clearly connecting RAC activity to invadopodia dynamics in melanoma (58) . Collectively, loss of RAC activity regulation may be a central feature of melanoma, a model that our data supports. The effect of altered RAC control by miR-382 reduction would be reinforced through derepression of ARPC2 and CTTN (and possibly other undescribed targets). The comparative importance of RAC1 and each identified target to these phenotypes remains for future study.
In summary, we identified two microRNA (miR-382 and miR516b) whose expression is altered during early stages of melanoma tumorigenesis and which suppress invasion and metastasis of melanoma cells. Moreover, we dissected the mechanistic basis for the metastasis-suppressive effects of miR-382, identifying several direct targets that may be critical mediators of its effects on invasion, metastasis, and matrix remodeling. Our data suggest that reduced expression of miR-382 in primary melanoma lesions promotes tumorigenesis through altered matrix remodeling because of derepression of regulators of the cytoskeleton. These findings 
